Percentage of peak-to-peak pulsatility of portal blood flow can predict right-sided congestive heart failure

Table 1 Clinical and biochemical data of patients with con-gestive heart failure (^-x±s)

	Control	Group 1	Group 2
Gender (M/F)	10/10	4/6	5/5
Age (y)	46 ± 12	50 ± 13	47 ± 19
Total protein (g/dL)	7.5 ± 0.6	7.1 ± 0.8	6.9 ± 1.1
Albumin (g/dL)	4.3 ± 0.2	3.9 ± 0.7	3.7 ± 0.5
Total serum bilirubin (mg/dL)	0.9 ± 0.4	1.3 ± 0.8	1.4 ± 0.8
AST (IU/L)	21 ± 6	31 ± 11	59 ± 29
ALT (IU/L)	24 ± 6	23 ± 8	35 ± 20
Prolonged prothrombin time (s)	-	1.1 ± 0.9	1.4 ± 0.8

Table 2 Cardiac profiles in patients with congestive heart failure [^-x±s, (n)]

	Group 1	Group2
CI [L/(min·m2)]	3.0 ± 1.4 (6)	2.4 ± 0.5 (7)
AOP (mmHg)	87.8 ± 11.7 (9)	87.6 ± 16.5 (8)
LVEDP (mmHg)	12.2 ± 9.3(10)	22.8 ± 13.0(9)
PWP (mmHg)	14.6 ± 7.3(9)	29.9 ± 9.3a (9)
PAP (mmHg)	25.0 ± 8.2(10)	46.3 ± 13.2a (9)
RAP (mmHg)	4.7 ± 2.4(10)	17.5 ± 5.7a (10)
RVEDP (mmHg)	6.4 ± 2.7(10)	18.3 ± 5.6a (10)

^aP < 0.001 vs group 1

Table 3 Portal profiles in patients with congestive heart failure (^-x±s)

	Control (n = 20)	Group1 (n = 10)	Group2 (n = 10)
Vmax (cm/s)	20.1 ± 3.1	24.5 ± 4.9	21.5 ± 6.1
Vmean (cm/s)	11.2 ± 1.9	14.0 ± 2.9	12.3 ± 3.5
Area (cm2)	1.01 ± 0.20	0.80 ± 0.17	0.94 ± 0.18
PBF (ml/min)	685 ± 136	678 ± 239	684 ± 191
PP (%)	23.3 ± 6.3	27.0 ± 8.9	86.6 ± 45.6a

^aP < 0.001 vs control and group 1.